Ultrasound Patent Infringement Claim Filed By Nycomed
Anglo-Norwegian group Nycomed Amersham has filed claims of patentinfringement in Holland and Germany against Mallinckrodt Medical BV and Mallinckrodt Medical GmbH, and their licensor Molecular Biosystems, in the District Court of the Hague in the Netherlands.
Nycomed is asserting that MBI's Optison ultrasound contrast agent, which is licensed throughout Europe to Mallinckrodt and is currently before the European Medicines Evaluation Agency for marketing approval, infringes Nycomed's European Patent 0 576 521 B1, which was granted September 3, 1997. Nycomed is also pursuing patent infringement claims against MBI's Optison in the USA under its analogous US patent.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze